

## Supplementary materials

**Title:** Prediction of Early Recurrence of Solitary Hepatocellular Carcinoma after Orthotopic Liver Transplantation

**Authors:** Jiliang Feng<sup>1†</sup>, Ruidong Zhu<sup>2†</sup>, Dezhao Feng<sup>3</sup>, Lu Yu<sup>1</sup>, Dawei Zhao<sup>4</sup>, Jushan Wu<sup>2</sup>, Chunwang Yuan<sup>5</sup>, Junmei Chen<sup>6</sup>, Yan Zhang<sup>1</sup>, Xiu Zheng<sup>1</sup>

### Table of contents:

Supplemental Table 1. Multicollinearity analysis

Supplemental Table 2. Comparing the performance of the model with single predictors and other criteria in the two cohorts

Supplemental Table 3. Test the statistical significance of the difference between the AUCs

Supplemental Table 4. Baseline clinical characteristics of patients in the validation cohort

**Supplemental Table 1: Multicollinearity analysis**

Variable	Adjusted R <sup>2</sup>	Unstandardized		Standardized		t	P	Tolerance	VIF
		Coefficients		Coefficients					
		B	Std. Error	Beta					
<b>Cirrhosis</b>		-0.116	0.175	-0.055	-0.667	0.507	0.868	1.153	
<b>Macroscopic vascular invasion</b>		0.095	0.111	0.077	0.851	0.397	0.718	1.392	
<b>Microscopic vascular invasion</b>	0.404	0.142	0.079	0.156	1.793	0.076	0.789	1.268	
<b>Histological grading</b>		0.029	0.058	0.045	0.499	0.619	0.738	1.355	
<b>CK19/GPC3 sub-typing</b>		0.217	0.067	0.298	3.216	0.002	0.695	1.439	
<b>AFP level</b>		0.152	0.085	0.162	1.803	0.075	0.742	1.348	

---

<b>Tumor diameter</b>	0.274	0.088	0.287	3.107	0.003	0.698	1.433
-----------------------	-------	-------	-------	-------	-------	-------	-------

---

Dependent Variable: recurrence; VIF, variance inflation factor; *Std. Error*, Standard error; CK, cytokeratin; GPC3, glypican 3; AFP, alpha fetoprotein.

A tolerance of less than 0.20 and/or a VIF of 10 and above indicates a multicollinearity problem.

Supplemental Table 2. Comparing the performance of the model with single predictors and other criteria in the two cohorts

Variable	Training cohort			Validation cohort		
	AUC	95% CI(Lower-Upper)	<i>P</i>	AUC	95% CI(Lower-Upper)	<i>P</i>
<b>CK19 expression</b>	0.612	0.484 0.741	=0.076	0.552	0.371 0.734	=0.560
<b>GPC3 expression</b>	0.716	0.617 0.815	=0.001	0.729	0.592 0.865	=0.011
<b>CK19/GPC3 sub-typing</b>	0.767	0.673 0.861	<0.001	0.750	0.618 0.883	=0.005
<b>Macroscopic vascular invasion</b>	0.641	0.515 0.768	=0.026	0.486	0.300 0.660	=0.874
<b>Microscopic vascular invasion</b>	0.679	0.567 0.791	=0.005	0.762	0.604 0.920	=0.004
<b>Tumor diameter</b>	0.744	0.634 0.855	<0.001	0.633	0.465 0.802	=0.138
<b>AFP level</b>	0.730	0.619 0.842	<0.001	0.719	0.571 0.867	=0.015
<b>Histological grading</b>	0.677	0.567 0.786	=0.005	0.730	0.572 0.887	=0.011
<b>Cirrhosis</b>	0.464	0.338 0.591	=0.570	0.524	0.350 0.697	=0.791
<b>Milan criteria</b>	0.708	0.586 0.829	=0.001	0.595	0.415 0.775	=0.290
<b>UCSF criteria</b>	0.646	0.518 0.773	=0.021	0.624	0.443 0.805	=0.169
<b>Fudan criteria</b>	0.593	0.464 0.722	=0.141	0.619	0.436 0.802	=0.186
<b>Hanzhou criteria</b>	0.569	0.441 0.697	=0.273	0.667	0.485 0.848	=0.064
<b>The novel model</b>	0.844	0.760 0.929	<0.001	0.876	0.759 0.994	<0.001

---

AUC, area under the curve; CI, confidence interval; CK, cytokeratin; GPC3, glypican 3; AFP, alpha-fetal protein; UCSF, the University of California

---

**Supplemental Table 3. Test the statistical significance of the difference between the AUCs**


---

Variable	The novel model					
	Training cohort		Validation cohort			
	95% CI (Lower-Upper)		<i>P</i>	95% CI (Lower-Upper)		<i>P</i>
<b>Milan criteria</b>	-0.001	0.274	=0.052	0.085	0.476	=0.005
<b>UCSF criteria</b>	0.055	0.342	=0.007	0.055	0.450	=0.012
<b>Fudan criteria</b>	0.111	0.392	=0.005	0.053	0.461	=0.014
<b>Hanzhou criteria</b>	0.131	0.420	=0.002	0.005	0.414	=0.045

---

---

**Supplemental Table 4. Baseline clinical characteristics of patients in the validation cohort**


---

<b>Variable</b>		<b>Recurrence</b>	<b>No</b>
<b>Age, years</b>	Median( range)	53(43-61)	48(35-73)
	mean±SD	52±4.8	50.4±8.3
<b>Gender, n (%)</b>			
	male	15(30.0)	28(56.0)
	female	0(0.0)	7(14.0)
<b>Cirrhosis, n (%)</b>			
	yes	14(28.0)	31(62.0)
	no	1(2.0)	4(8.0)
<b>Etiology, n (%)</b>			
	HBV infection	14(28.0)	28(56.0)
	HCV infection	0(0)	4(8.0)

---

---

	alcohol abuse	0(0)	0(0)
	Budd-Chiari syndrome	0(0)	0(0)
	schistosome infection	0(0)	0(0)
	HBV infection+ alcohol abuse	0(0)	0(0)
	HBV+HEV infection	0(0)	0(0)
	HBV+HCV infection	1(0)	2(4.0)
	AIH	0(0)	1(2.0)
<b>Child-Pugh score</b>	A	8(16.0)	11(22.0)
	B	4(8.0)	18(36.0)
	C	3(6.0)	6(12.0)
<b>MELD score</b>	Median( range)	8(2-19)	8(3-27)
<b>AFP level</b>			
	≤20 ng/mL	1(2.0)	13(26.0)

---



---

>20 ng/ mL, ≤200 ng/mL	1(2.0)	7(14.0)
>200 ng/ mL, ≤400 ng/mL	4(8.0)	5(10.0)
>400 ng/ mL	9(18.0)	10(20.0)
<b>CK19/GPC3</b>		
<b>sub-typing, n (%)</b>		
CK19+/GPC3+	2(4.0)	1(2.0)
CK19-/GPC3+	13(26.0)	18(36.0)
CK19-/GPC3-	0(0)	16(32.0)
<b>Histological grading,</b>		
<b>n (%)</b>		
poorly	10(20.0)	8(16.0)
moderately	3(6.0)	14(28.0)
well	2(4.0)	13(26.0)

---

<b>Macroscopic vascular invasion, n (%)</b>	yes	0(0)	1(2.0)
	no	15(30.0)	34(68.0)
<b>Microscopic vascular invasion, n (%)</b>	yes	10(20.0)	5(10.0)
	no	5(10.0)	30(60.0)
<b>Tumor diameter, n (%)</b>			
	≤3cm	5(10.0)	19(38.0)
	>3cm, ≤5cm	5(10.0)	11(22.0)
	>5cm	5(10.0)	5(10.0)
<b>Milan criteria, n (%)</b>			
	within	10(20.0)	30(60.0)

---

	beyond	5(10.0)	5(10.0)
<b>UCSF criteria, n (%)</b>			
	within	10(20.0)	32 (64.0)
	beyond	5(10.0)	3(6.0)
<b>Fudan criteria, n (%)</b>			
	within	11(22.0)	34(68.0)
	beyond	4(8.0)	1(2.0)
<b>Hangzhou criteria, n (%)</b>			
	within	10(20.0)	35(70.0)
	beyond	5(10.0)	0(0.0)

---

SD, standard deviation; HBV, hepatitis C virus; HCV, hepatitis C virus; CK19, cytokeratin 19; GPC3, glypican 3; UCSF, University of California, San Francisco